Recent improvement of survival prognosis after pulmonary metastasectomy and advanced chemotherapy for patients with colorectal cancer

on behalf of the Metastatic Lung Tumor Study Group of Japan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

New chemotherapeutic regimens (i.e. FOLFOX or FOLFIRI with molecular targeted drugs) have improved the prognosis of patients with unresectable or recurrent colorectal cancer. To estimate the prognostic impact of these chemotherapies, we examined the chronological change in survival rates of patients who underwent pulmonary metastasectomy for colorectal cancer metastasis. METHODS: Using a large database, we conducted a retrospective, multi-institutional study to collect data of 1223 eligible patients from 26 institutions who had undergone pulmonary metastasectomy with curative intent. We divided those patients who underwent metastasectomy in different time periods according to the major trend of chemotherapy regimens for recurrent colorectal cancer: those who underwent metastasectomy between 1990 and 1999 (N = 451, Group A), between 2000 and 2004 (N = 433, Group B) or between 2005 and 2007 (N= 339, Group C). RESULTS: Five-year overall survival rates after metastasectomy were 45% in Group A, 56% in Group B and 66% in Group C (P < 0.0001) whereas rates after metastasectomy plus chemotherapy were 32% in Group A, 47% in Group B and 70% in Group C (P = 0.0059). The prognosis of patients who underwent both metastasectomy and chemotherapy in Group C was significantly better than that of the other two groups. Overall survival of patients who did not receive chemotherapy was not significantly different between the groups. CONCLUSION: Survival rates of patients after pulmonary metastasectomy for colorectal cancer metastasis who underwent chemotherapy have increased over the years. It implies that newer chemotherapy regimens might have had a positive impact on these patients.

Original languageEnglish
Article numberezw401
Pages (from-to)869-873
Number of pages5
JournalEuropean Journal of Cardio-thoracic Surgery
Volume51
Issue number5
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Metastasectomy
Colorectal Neoplasms
Drug Therapy
Lung
Survival
Survival Rate
Neoplasm Metastasis
Databases

Keywords

  • Adjuvant chemotherapy
  • Colorectal cancer
  • Metastasectomy
  • Pulmonary metastasis
  • Survival rate

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Recent improvement of survival prognosis after pulmonary metastasectomy and advanced chemotherapy for patients with colorectal cancer. / on behalf of the Metastatic Lung Tumor Study Group of Japan.

In: European Journal of Cardio-thoracic Surgery, Vol. 51, No. 5, ezw401, 01.05.2017, p. 869-873.

Research output: Contribution to journalArticle

@article{c9c7c827fe3548c4a68a1dbfc944c581,
title = "Recent improvement of survival prognosis after pulmonary metastasectomy and advanced chemotherapy for patients with colorectal cancer",
abstract = "New chemotherapeutic regimens (i.e. FOLFOX or FOLFIRI with molecular targeted drugs) have improved the prognosis of patients with unresectable or recurrent colorectal cancer. To estimate the prognostic impact of these chemotherapies, we examined the chronological change in survival rates of patients who underwent pulmonary metastasectomy for colorectal cancer metastasis. METHODS: Using a large database, we conducted a retrospective, multi-institutional study to collect data of 1223 eligible patients from 26 institutions who had undergone pulmonary metastasectomy with curative intent. We divided those patients who underwent metastasectomy in different time periods according to the major trend of chemotherapy regimens for recurrent colorectal cancer: those who underwent metastasectomy between 1990 and 1999 (N = 451, Group A), between 2000 and 2004 (N = 433, Group B) or between 2005 and 2007 (N= 339, Group C). RESULTS: Five-year overall survival rates after metastasectomy were 45{\%} in Group A, 56{\%} in Group B and 66{\%} in Group C (P < 0.0001) whereas rates after metastasectomy plus chemotherapy were 32{\%} in Group A, 47{\%} in Group B and 70{\%} in Group C (P = 0.0059). The prognosis of patients who underwent both metastasectomy and chemotherapy in Group C was significantly better than that of the other two groups. Overall survival of patients who did not receive chemotherapy was not significantly different between the groups. CONCLUSION: Survival rates of patients after pulmonary metastasectomy for colorectal cancer metastasis who underwent chemotherapy have increased over the years. It implies that newer chemotherapy regimens might have had a positive impact on these patients.",
keywords = "Adjuvant chemotherapy, Colorectal cancer, Metastasectomy, Pulmonary metastasis, Survival rate",
author = "{on behalf of the Metastatic Lung Tumor Study Group of Japan} and Jun Nakajima and Tomohiko Iida and Sakae Okumura and Hirotoshi Horio and Hisao Asamura and Yuichi Ozeki and Norihiko Ikeda and Haruhisa Matsuguma and Masayuki Chida and Hajime Otsuka and Masafumi Kawamura",
year = "2017",
month = "5",
day = "1",
doi = "10.1093/ejcts/ezw401",
language = "English",
volume = "51",
pages = "869--873",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Recent improvement of survival prognosis after pulmonary metastasectomy and advanced chemotherapy for patients with colorectal cancer

AU - on behalf of the Metastatic Lung Tumor Study Group of Japan

AU - Nakajima, Jun

AU - Iida, Tomohiko

AU - Okumura, Sakae

AU - Horio, Hirotoshi

AU - Asamura, Hisao

AU - Ozeki, Yuichi

AU - Ikeda, Norihiko

AU - Matsuguma, Haruhisa

AU - Chida, Masayuki

AU - Otsuka, Hajime

AU - Kawamura, Masafumi

PY - 2017/5/1

Y1 - 2017/5/1

N2 - New chemotherapeutic regimens (i.e. FOLFOX or FOLFIRI with molecular targeted drugs) have improved the prognosis of patients with unresectable or recurrent colorectal cancer. To estimate the prognostic impact of these chemotherapies, we examined the chronological change in survival rates of patients who underwent pulmonary metastasectomy for colorectal cancer metastasis. METHODS: Using a large database, we conducted a retrospective, multi-institutional study to collect data of 1223 eligible patients from 26 institutions who had undergone pulmonary metastasectomy with curative intent. We divided those patients who underwent metastasectomy in different time periods according to the major trend of chemotherapy regimens for recurrent colorectal cancer: those who underwent metastasectomy between 1990 and 1999 (N = 451, Group A), between 2000 and 2004 (N = 433, Group B) or between 2005 and 2007 (N= 339, Group C). RESULTS: Five-year overall survival rates after metastasectomy were 45% in Group A, 56% in Group B and 66% in Group C (P < 0.0001) whereas rates after metastasectomy plus chemotherapy were 32% in Group A, 47% in Group B and 70% in Group C (P = 0.0059). The prognosis of patients who underwent both metastasectomy and chemotherapy in Group C was significantly better than that of the other two groups. Overall survival of patients who did not receive chemotherapy was not significantly different between the groups. CONCLUSION: Survival rates of patients after pulmonary metastasectomy for colorectal cancer metastasis who underwent chemotherapy have increased over the years. It implies that newer chemotherapy regimens might have had a positive impact on these patients.

AB - New chemotherapeutic regimens (i.e. FOLFOX or FOLFIRI with molecular targeted drugs) have improved the prognosis of patients with unresectable or recurrent colorectal cancer. To estimate the prognostic impact of these chemotherapies, we examined the chronological change in survival rates of patients who underwent pulmonary metastasectomy for colorectal cancer metastasis. METHODS: Using a large database, we conducted a retrospective, multi-institutional study to collect data of 1223 eligible patients from 26 institutions who had undergone pulmonary metastasectomy with curative intent. We divided those patients who underwent metastasectomy in different time periods according to the major trend of chemotherapy regimens for recurrent colorectal cancer: those who underwent metastasectomy between 1990 and 1999 (N = 451, Group A), between 2000 and 2004 (N = 433, Group B) or between 2005 and 2007 (N= 339, Group C). RESULTS: Five-year overall survival rates after metastasectomy were 45% in Group A, 56% in Group B and 66% in Group C (P < 0.0001) whereas rates after metastasectomy plus chemotherapy were 32% in Group A, 47% in Group B and 70% in Group C (P = 0.0059). The prognosis of patients who underwent both metastasectomy and chemotherapy in Group C was significantly better than that of the other two groups. Overall survival of patients who did not receive chemotherapy was not significantly different between the groups. CONCLUSION: Survival rates of patients after pulmonary metastasectomy for colorectal cancer metastasis who underwent chemotherapy have increased over the years. It implies that newer chemotherapy regimens might have had a positive impact on these patients.

KW - Adjuvant chemotherapy

KW - Colorectal cancer

KW - Metastasectomy

KW - Pulmonary metastasis

KW - Survival rate

UR - http://www.scopus.com/inward/record.url?scp=85019123321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019123321&partnerID=8YFLogxK

U2 - 10.1093/ejcts/ezw401

DO - 10.1093/ejcts/ezw401

M3 - Article

C2 - 28369355

AN - SCOPUS:85019123321

VL - 51

SP - 869

EP - 873

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 5

M1 - ezw401

ER -